Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Triglyceride levels, pancreatitis and choice of lipid-modifying therapy.

Preiss D.

Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):193-5. doi: 10.1586/egh.12.79. No abstract available.

PMID:
23445227
2.

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.

Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM.

Br J Dermatol. 2013 Jan;168(1):192-200. doi: 10.1111/bjd.12042. Epub 2012 Dec 3.

PMID:
22963233
3.

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.

Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ.

JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439.

PMID:
22910758
4.

Management of hypertriglyceridemia in the diabetic patient.

Jialal I, Amess W, Kaur M.

Curr Diab Rep. 2010 Aug;10(4):316-20. doi: 10.1007/s11892-010-0124-4. Review.

5.

Concerns about heparin therapy for hypertriglyceridemia.

Whayne TF Jr.

Arch Intern Med. 2010 Jan 11;170(1):108-9; author reply 109. doi: 10.1001/archinternmed.2009.461. No abstract available.

PMID:
20065209
6.

Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis.

Cole RP.

Arch Intern Med. 2009 Aug 10;169(15):1439-41. doi: 10.1001/archinternmed.2009.221.

PMID:
19667310
7.

Treating hypertriglyceridemia.

Holub BJ.

CMAJ. 2007 Sep 11;177(6):604; author reply 604-5. No abstract available.

8.

Treating hypertriglyceridemia.

Röggla G, Fasan M, Kapiotis S.

CMAJ. 2007 Sep 11;177(6):603; author reply 604-5. No abstract available.

9.

Treating hypertriglyceridemia.

Yavasoglu I, Kadikoylu G, Bolaman Z.

CMAJ. 2007 Sep 11;177(6):603-4; author reply 604-5. No abstract available.

10.

Hypertriglyceridemia: its etiology, effects and treatment.

Yuan G, Al-Shali KZ, Hegele RA.

CMAJ. 2007 Apr 10;176(8):1113-20. Review.

11.

Expert commentary: the safety of fibrates in lipid-lowering therapy.

Brown WV.

Am J Cardiol. 2007 Mar 19;99(6A):19C-21C. Epub 2006 Nov 29. Review.

PMID:
17368273
12.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
13.

Drug treatment of combined hyperlipidemia.

Wierzbicki AS, Mikhailidis DP, Wray R.

Am J Cardiovasc Drugs. 2001;1(5):327-36. Review.

PMID:
14728015
14.

Management of protease inhibitor-associated hyperlipidemia.

Penzak SR, Chuck SK.

Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.

PMID:
14727985
15.

Intervention for hyperlipidemia associated with protease inhibitors.

Melroe NH, Kopaczewski J, Henry K, Huebsch J.

J Assoc Nurses AIDS Care. 1999 Jul-Aug;10(4):55-69. Erratum in: J Assoc Nurses AIDS Care 1999 Sep-Oct;10(5):109.

PMID:
10394560
16.

Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.

Garg A, Grundy SM.

Diabetes. 1989 Mar;38(3):364-72. Erratum in: Diabetes 1990 Oct;39(10):1313.

PMID:
2917701
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk